Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients

NCT00251004 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00251004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00251004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant Recipients
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2005
Completion date
October 31, 2009
Enrollment
833 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft rejection, kidney transplantation